title: [Treatment of chronic obstructive pulmonary disease].
abstract: Chronic obstructive pulmonary disease (COPD) is a highly prevalent condition and most epidemiological studies have found that COPD prevalence, morbidity and mortality have increased over the last few years. Recent trials suggest that treatments are improving. Several studies have demonstrated the usefulness of the long-acting inhaled beta-2-agonists. Inhaled glucocorticoids, although unable to alter the progression of COPD, may reduce the frequency of acute exacerbations and health status deterioration in a limited group of patients with COPD. Likewise, these drugs may offer benefits in combination with long-acting inhaled beta-agonists. Finally, a better understanding of the molecular and cellular mechanisms involved in COPD pathogenesis should lead to effective treatments that slow or halt the course of the disease. New classes of agents such as the phosphodiesterase inhibitors are now in development.
authors.affiliation: Servicio de Medicina Interna, Hospital Arquitecto Marcide, Ferrol. fjf-fernandez@terra.es
authors.forename: F J
authors.initials: FJ
authors.lastname: Fernández-Fernández
authors.forename: E
authors.initials: E
authors.lastname: Ameneiros-Lago
authors.forename: J
authors.initials: J
authors.lastname: González Moraleja
authors.forename: G
authors.initials: G
authors.lastname: Pía Iglesias
authors.forename: F S
authors.initials: FS
authors.lastname: Martínez-Debén
authors.forename: P
authors.initials: P
authors.lastname: Sesma
mesh_terms: D001993:Bronchodilator Agents / Q000627:therapeutic use*; D006801:Humans; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy*
chemical_list: D001993:Bronchodilator Agents